Close

NEWS

IBI Lorenzini among the "BIG" of the Made in Italy

01 December 2017

Rome, 1 December 2017: from Lazio to the world. The pharmaceutical company IBI Lorenzini, chaired by Camilla Borghese Khevenhüller, has been awarded the “100 Italian Excellences” award, established by editor Riccardo Dell’Anna as a recognition for those companies and personalities that with their work and their skills contribute to the growth of the Made in Italy around the world. The official awarding ceremony took place at Palazzo Montecitorio, Rome, in the presence of national institutions, local bodies, universities and associations, and under the patronage of the Presidency of the Council of Ministers.

Strongly rooted in the Italian region of Aprilia, IBI Lorenzini, still a family-run company under a female leadership, has a centennial scientific tradition in the sector of the production of antibiotics, sterile penicillin, and injectable drugs. Thanks to its high level of professional know-how and the continuous commitment towards innovation and quality, the company exports 2/3 of its own turnover all over the world, from Europe to Asia, From America to Australia.

“We are a global company, but with a decidedly local DNA,” says Camilla Borghese Khevenhüller, President of IBI Lorenzini “from which still today we draw our strength to compete all over the world, with 100 years of experience, but also with our wealth of creativity and our spasmodic attention to our stakeholders. If there is a secret for success, may be is to always aim at quality and invest in continuous innovation. This has brought us to strongly commit to the challenge of Industry 4.0 and implement, among the firsts in Italy, drug tracking systems to fight the threat of counterfeited drugs. 

Latest news

undefined

Scuola-lavoro in campo 30 big del farmaceutico

Farmindustria, insieme alla Fondazione Edison, ha presentato i numeri del primo progetto pilota di alternanza scuola-lavoro nel settore farmaceutico. 

Read all
undefined

Imprese, nel Lazio aumentano i ricavi ma la Toscana fa meglio

Presentata l’inchiesta realizzata da Industria Felix Magazine e Cerved su 30mila bilanci di pmi e grandi aziende

Read all
undefined

REVER3MAB: "An ambitious project for the development of an innovative biological drug"?

IBI collaborates in the development of an innovative biological drug to revert resistance to conventional cancer treatments: project: REVER3MAB (EU, State and Region)

Read all

See all news items

Thank you

We sent you an email. To activate the newsletter click on the link you will find in the message, thank you!

Sign up for the newsletter

Dichiarazione in merito al GDPR (Regolamento Generale Protezione dei Dati)

In caso di sottoscrizione Newsletter dovrai confermare l’iscrizione per mezzo di mail di conferma inviata all’indirizzo inserito. In tal caso il trattamento prevede:

la profilazione dell’utente in gruppi, status, preferenze secondo quanto indicato e dedotto dalle informazioni inviate tramite il form o successiva autonoma profilazione.
l’utilizzo del dato per l’invio di comunicazione a mezzo digitale (email, whatsapp) e non (cartaceo) avente scopo informativo/commerciale.
l'utilizzo della mail per la generazione di campagne marketing e informative personalizzate, digitali e non.

Cancel
CHIUDI

Private area

Sign up
Do not remember your password?
Cancel Log in

Log in to restricted area

Cancel Log in

Registration

Notice on the treatment of personal data

Dear visitor, in the following sections we will describe how the reserved area of the www.ibi-lorenzini.it website is managed as far as processing personal data of users. The notice is issued pursuant to art. 13 of EU Regulation 679/2016 (hereinafter also the Regulation) on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and applies to those who interact with the website of Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. (hereinafter I.B.I.), which can be accessed at the following address: www.ibi-lorenzini.it, the opening page of the official I.B.I. website. The notice only applies to the I.B.I. website. It does not apply to any other websites that the user may access through links.

  1. The processing of the personal data that you supply, which are also used for the creation of your user profile, and which will be included in the “Doctors’ Details” database, has the following purposes:

  • carry out medical sales related activities for drugs for human consumption. Istituto Biochimico Italiano Giovanni Lorenzini S.p.A. and Ibigen S.r.l., part of the same company group (hereinafter also Ibigen Group), carry out such activities in compliance with the provisions of the current regulations, with particular, but not exclusive, attention to Italian Legislative Decree no. 219 of 24.04.2006 and subsequent modifications. In view of the objectives of the Ibigen Group, it is important to point out that the processing activities do not deal with any special data. The supply of the data for the medical sales activities is necessary, and failure to provide consent will make it impossible for us to fulfil the above objectives;

  • forwarding of invitations or information on congresses, conferences, seminars, communications on initiatives promoted or sponsored by the Ibigen group, regular or occasional publications, information on new products, methods and services. Such activities are carried out by e-mail, fax, SMS, normal post or telephone. The supply of the data for such purposes is optional, and failure to supply them will result in the information not being forwarded.

  1. As far as the creation of your profile on our website, we remind you that your password is strictly confidential and should not be disclosed.
  2. Your data will not be disclosed, but may be shared with individuals, companies, associations or professional studios providing support or consultancy services to the Ibigen Group, the medical sales representative network, our suppliers and any sub-suppliers - from time to time entrusted with activities connected with the above objectives -, mailing or statistical survey companies, or companies for the forwarding of scientific documentation, and individuals authorised to access the data by law and/or pursuant to secondary regulations.
  3. Such people may only acquire knowledge of your personal data for the above mentioned purposes.
  4. The Owners of the Treatment (Data Controllers) are the two companies of the Ibigen Group with legal headquarters at Via Fossignano no. 2, Aprilia (LT), Italy.
  5. Personal data are processed using manual and automated means, for the time necessary for reaching the objectives for which they were collected. Special safety measures are in place to avoid data loss, unlawful or incorrect use and unauthorised access.
  6. Lastly, we also inform you that you can at any time exercise the rights contemplated by the Regulation, and in particular request access to the data, their correction, update and block, or you can withdraw your consent, or request the limitation of the processing or the cancellation of the data. As data subject, you also have the right to issue a complaint with the relevant control Authority. Such rights may be exercised in writing to the following e-mail address: info@ibi-lorenzini.com.
  7. The Data Protection Officer may be contacted at the following e-mail address: dpo_ibi@protectiontrade.it

* Required fields

Cancel